Treating Triple Negative Breast Cancer
SLU ID 21-011 | GPER-PROTAC
Intellectual Property Status
Seeking
Patent-ability under review
Know-how based
Licensee
Development partner
Commercial partner
Investment
University spin out
Background
Triple negative breast cancer is a subtype that is highly aggressive. It has poor survival rates, primarily because there is a lack of molecular targets.
Overview
Researchers at Saint Louis University at the University of Iowa have identified small molecule therapeutics that demonstrate promise in treating triple negative breast cancer without inducing potential drug resistance. The molecules may also be useful for treating a variety of other cancers.
Benefits
The potential benefits this technology include:
Increasing the survival rate of patients
Increasing the efficacy of treatments
Increasing the number of treatment options
Minimizing the potential for drug resistance
Applications
Potential applications of this technology include:
Treating triple negative breast cancer
Treating endocrine-resistant cancer
Treating ovarian cancer
Treating endometrial cancer
Treating prostate cancer
Treating colon cancer
Opportunity
Saint Louis University and the University of Iowa are seeking partners to further develop and commercialize this technology.